Hospitalization Resource Utilization and Costs Among Medicaid Insured Patients With Schizophrenia With Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy
Authors:
- Steve OffordSOSteve Offord
- Donna ZubekDZDonna Zubek
- Gina LauGLGina Lau
- Jay LinJLJay Lin
- Craig KarsonCKCraig Karson
- 1 February 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 34 (1) , 30-35
Abstract
This study evaluated the impact of using long-acting injectable (LAI) antipsychotics for a longer treatment duration versus a short duration on health care resource utilization among Medicaid-insured schizophrenia patients. Schizophrenia patients 13 years or older initiating LAI antipsychotics were identified from the Truven Health Analytics MarketScan Research Medicaid database between July 1, 2005, and June 30, 2010. The study population was grouped into 2 study cohorts (longer-usage-duration cohort: ≥ 180 days of supply and short-usage-duration cohort: <180 days of supply). Hospitalization-related resource utilization and costs were determined during a variable follow-up period and compared at the unadjusted and adjusted levels. Of the 5694 patients identified, 2838 patients were treated with LAI antipsychotics for a mean duration of 604 (SD, 432) days (mean age, 38.91 years), and 2856 were treated for 86 (SD, 43) days (mean age, 39.96 days). Total hospital lengths of stay, all cause (6.56 [SD, 18.63] vs 4.93 [SD, 13.40] days, P < 0.001) and schizophrenia related (5.18 [SD, 14.96] vs 4.16 [SD, 11.94] days, P = 0.005), and the mean number of hospitalizations, all cause (0.79 [SD, 1.78] vs 0.61 [SD, 1.41], P < 0.001) and schizophrenia related (0.63 [SD, 1.55] vs 0.51 [SD, 1.26], P = 0.001), were lower for the longer-usage-duration cohort. Cox regression results showed that using LAI antipsychotics for a longer duration was correlated with longer time to the first hospitalization for any cause and for schizophrenia. After multivariate regression, longer usage duration of LAI antipsychotics was associated with a decreased number of hospitalizations (-0.15 per year, P < 0.001), a decreased hospital length of stay (-1.50 days, P < 0.001), and reduced hospital payment (-26%, P < 0.001). Patients who are treated with LAI antipsychotics for a longer versus shorter duration use hospital resources less.Keywords
This publication has 18 references indexed in Scilit:
- Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational studyBMC Psychiatry, 2011
- Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnnals of General Psychiatry, 2011
- Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophreniaPatient Preference and Adherence, 2010
- Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare SystemJournal of Medical Economics, 2009
- Risperidone long‐acting injection: a 6‐year mirror‐image study of healthcare resource useActa Psychiatrica Scandinavica, 2009
- Loss of Health Insurance Among Non-elderly Adults in MedicaidJournal of General Internal Medicine, 2008
- Impact of risperidone long acting injection on resource utilization in psychiatric secondary careJournal of Psychopharmacology, 2008
- Health resource utilization associated with switching to risperidone long‐acting injectionActa Psychiatrica Scandinavica, 2006
- Prevalence of and Risk Factors for Medication Nonadherence in Patients With SchizophreniaThe Journal of Clinical Psychiatry, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987